Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pravastatin Sodium

FDA-approved product (tablet, oral), marketed as Pravachol, Pravastatin Sodium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Pravastatin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atherosclerosis
  • Cardiovascular disease
  • Coronary artery disease
  • Coronary atherosclerosis
  • Familial hypercholesterolemia
  • Hypercholesterolemia
  • Myocardial infarction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis47.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pravastatin Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pravastatin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin

    NCT01057654 · start 1996-01

    Registered record
    Registry ID
    NCT01057654
    Conditions
    Hypercholesterolemia; Hyperlipoproteinemia
    Interventions
    Pravastatin; Lifibrol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1996-01
    Completion
    1998-06
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia; Hyperlipoproteinemia
    InterventionPravastatin; Lifibrol
    PhasePhase 3
    Registry statusCompleted

  • Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)

    NCT00211705 · start 1994-02

    Registered record
    Registry ID
    NCT00211705
    Conditions
    Hyperlipidemia
    Interventions
    Diet; Diet+pravastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1994-02
    Completion
    2004-03
    Enrolment
    8,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemia
    InterventionDiet; Diet+pravastatin
    PhasePhase 4
    Registry statusCompleted

  • A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

    NCT00000941

    Registered record
    Registry ID
    NCT00000941
    Conditions
    HIV Infections
    Interventions
    Pravastatin sodium; Simvastatin; Atorvastatin calcium; Ritonavir; Nelfinavir mesylate; Saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2002-03
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionPravastatin sodium; Simvastatin; Atorvastatin calcium; Ritonavir +2 more
    PhasePhase 1
    Registry statusCompleted

  • Prevention of Kidney Transplant Rejection

    NCT00005010

    Registered record
    Registry ID
    NCT00005010
    Conditions
    End-Stage Renal Disease; Chronic Allograft Nephropathy
    Interventions
    Irbesartan; Pravastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2004-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd-Stage Renal Disease; Chronic Allograft Nephropathy
    InterventionIrbesartan; Pravastatin
    PhasePhase 3
    Registry statusCompleted

  • Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

    NCT00006412

    Registered record
    Registry ID
    NCT00006412
    Conditions
    HIV Infections; Lipodystrophy
    Interventions
    Pravastatin sodium; Fenofibrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2003-05
    Enrolment
    630

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Lipodystrophy
    InterventionPravastatin sodium; Fenofibrate
    PhasePhase 3
    Registry statusCompleted